The biopharma industry is experiencing a resurgence, driven by robust venture investments, consistent mergers and acquisitions (M&A), and a steadily expanding IPO market. According to J.P. Morgan’s recent second-quarter licensing and venture report, the industry is poised for significant growth as we move through 2024.
Surge in Venture Investments
In the second quarter, biopharma companies attracted $7.6 billion in private financing across 107 investments, matching the number of rounds seen in the first quarter. This influx of capital marks a notable increase from previous quarters, indicating a growing confidence in the sector. The report highlights that these high-dollar rounds are pouring into biopharma and platform research, regardless of the companies’ clinical stages.
J.P. Morgan anticipates that venture dollar volume could reach $28.2 billion by the end of the year, potentially breaking a two-year downtrend. However, this figure will still fall short of the record $43.8 billion raised in 2021 across 750 rounds.
Notable Fundraising Highlights
Several biopharma companies stood out with significant fundraising achievements. Xaira Therapeutics secured a massive $1 billion in committed capital in April, while Formation Bio raised $372 million in a Series D round in June. AltruBio also made headlines with a $225 million Series B raise in May. Early-stage funding remained robust, with seed and Series A fundraising totaling $5.1 billion across 105 rounds in the first half of the year.
Interestingly, the focus of fundraising has shifted towards companies with candidates in clinical development. Phase 1 companies raised a median round of $76 million in the second quarter, double the figure from the previous year. Phase 3 companies saw even more significant gains, with a median round size of $100 million, more than double the full-year 2023 value for late-stage companies.
M&A and Licensing Trends
The M&A landscape remains vibrant, with 26 acquisitions totaling $17.9 billion in the second quarter alone. The industry is on track to reach around 100 total deals in 2024. Major acquisitions include Vertex Pharmaceuticals’ $4.9 billion purchase of Alpine Immune Sciences and Merck’s $1.3 billion acquisition of Eyebiotech.
Licensing partnerships continue to dominate deal activity, particularly those focused on biologics and small molecules. However, there’s a noticeable trend towards smaller upfront payments and larger milestone-based payments, as in-licensing partners seek to mitigate economic risk. For example, upfront payments represented just 6% of the total deal value for licensing transactions, down from a peak of 13% in 2019. Notable deals include Sanofi and Novavax’s $500 million agreement for the COVID-19 vaccine Nuvaxovid, and Novartis’s deals with PeptiDream and Arvinas for significant upfront sums.
A Growing IPO Market
The IPO market also showed signs of life, with $1.9 billion raised across 10 market debuts in the first half of the year. Most of these IPOs involved companies with active clinical programs, signaling a strong market interest in later-stage biopharma entities. The largest IPOs included CG Oncology’s $437 million entry and Kyverna Therapeutics’ $367 million. Even Alumis, despite downsizing its IPO at the last minute, managed to raise a notable $210 million.
Looking Ahead
J.P. Morgan expects the biopharma industry’s growth trajectory to continue as interest rates stabilize and potentially decrease by September. With a strong pipeline of investments, M&A deals, and IPOs, the sector is well-positioned for a dynamic and prosperous 2024. As the industry adapts to changing market dynamics and continues to innovate, it will be exciting to see how these trends evolve and shape the future of biopharma.
